Biocon has launched its new manufacturing facility in Bengaluru to provide pen-like insulin devices for diabetes patients. It aims to strengthen the company’s insulin portfolio.
The unit has been set over a spread area of 10000 sq feet, with an aim to provide an insulating device for every one in five insulin dependent diabetes patient. The devices will be supplied in India and abroad, both.
Our aim is to provide insulin products to at least one in five insulin-dependent diabetes patients, anywhere in the world. This new device facility is a key milestone in our journey towards that goal,” Biocon Chairperson & Managing Director, Kiran Mazumdar-Shaw said.
The facility will enable us to not only fulfil our commitment to ‘Make in India for the World’ but also deliver on the promise of affordable access to healthcare for all, she added.
“Through our product Basalog One, we will be providing a high end patient-friendly basal insulin glargine pen in India first and subsequently in the global markets,” she said.
The global insulin delivery devices market, estimated at USD 9.4 billion in 2014, is expected to grow at a CAGR of 7 per cent to reach an estimated USD 14.1 billion in 2020.